155 results
8-K
EX-99.1
VNDA
Vanda Pharmaceuticals Inc
3 Aug 22
Vanda Pharmaceuticals Reports Second Quarter 2022 Financial Results
4:12pm
, 2022.
“During the second quarter we made significant progress towards commercializing our products and improving access to HETLIOZ® for patients … to broaden access to HETLIOZ® for patients with Non-24 and patients with nighttime sleep disturbances in Smith-Magenis Syndrome (SMS).
In July 2022
8-K
EX-99.2
VNDA
Vanda Pharmaceuticals Inc
8 Sep 11
Regulation FD Disclosure
12:00am
Access Day
ROCKVILLE, MD, August 31, 2011 /PRNewswire-FirstCall/ — Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ: VNDA), a biopharmaceutical company … corporate website, where it also will be archived for 30 days. To access the presentation, log on to http://www.vandapharma.com and click
8-K
EX-99.1
VNDA
Vanda Pharmaceuticals Inc
26 May 20
Vanda Pharmaceuticals Announces Virtual 2020 Stockholder Meeting
7:11am
and www.proxyvote.com).
If you are a stockholder of record, to gain access to the virtual Meeting go to www.virtualshareholdermeeting.com/VNDA2020 … at www.vandapharma.com and www.proxyvote.com). Only one stockholder per 16-digit control number can access the virtual 2020 Annual Meeting at the website
DEFA14A
VNDA
Vanda Pharmaceuticals Inc
26 May 20
Additional proxy soliciting materials
7:13am
Vanda’s website at www.vandapharma.com and www.proxyvote.com).
If you are a stockholder of record, to gain access to the virtual Meeting go … in the Proxy Statement and available Vanda’s website at www.vandapharma.com and www.proxyvote.com). Only one stockholder per 16-digit control number can access
8-K
EX-99.1
VNDA
Vanda Pharmaceuticals Inc
31 Jan 14
Fda Approves Hetlioztm (Tasimelteon) for the Treatment of
12:00am
Officer. “We are committed to providing much needed support to patients with Non-24 and facilitating access to this new therapeutic option.”
The approval … time, these patients have access to an approved, safe and effective treatment for their difficult debilitating disorder.”
Vanda anticipates making
8-K
EX-99.1
281edmxgln9c454pqj
5 May 22
Vanda Pharmaceuticals Reports First Quarter 2022 Financial Results
12:00am
DEFA14A
cgnriuuh 68k99g7ioh
27 Apr 18
Additional proxy soliciting materials
7:04am
DEFA14A
2ezucx0m
26 Apr 13
Additional proxy soliciting materials
12:00am
8-K
EX-99.1
hn7cf82a
4 Feb 22
Vanda Pharmaceuticals Reports Results from the Phase III Study of Tradipitant in Gastroparesis
7:07am
DEFA14A
dittdn9t
7 Apr 14
Additional proxy soliciting materials
12:00am
8-K
EX-99.1
3t9 a17fbs2ziofy
10 Apr 14
Other Events
12:00am
8-K
EX-99.1
jgzg1wmzvvwhx 7ghi
5 Aug 20
Vanda Pharmaceuticals Reports Second Quarter 2020 Financial Results
4:06pm
8-K
EX-99.1
zgs3dw2gws3lw kbw
27 Oct 14
Vanda Pharmaceuticals Reports Third Quarter 2014 Financial Results
12:00am
8-K
EX-99.1
u3c7blcd4gs6vqm
2 Nov 22
Vanda Pharmaceuticals Reports Third Quarter 2022 Financial Results
4:08pm
8-K
EX-99.1
v6wuq9eoi
4 Jun 14
Regulation FD Disclosure
12:00am
8-K
EX-99.1
d9ljib38 mofkt
3 Nov 21
Vanda Pharmaceuticals Reports Third Quarter 2021 Financial Results
4:08pm